ELCC 2017 | Biomarker testing in NSCLC
Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE from the University of Aberdeen, Aberdeen, UK discusses the multitude of biomarker tests available for the treatment of non-small cell lung cancer (NSCLC). Dr Kerr explains how these tests can identify the best treatment options for patients. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.
Get great new content delivered to your inboxSign up